ArticleParasites & vectors2010
Lipoprotein biosynthesis as a target for anti-Wolbachia treatment of filarial nematodes.
Article in Parasites & vectors, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Control of arboviruses vectors using biological control by Wolbachia pipientis: a short review.Archives of microbiology · 2022Pooled it
- Retarded Onchocerca volvulus L1 to L3 larval development in the Simulium damnosum vector after anti-wolbachial treatment of the human host.Parasites & vectors · 2012Trial
- Contemporary exploitation of natural products for arthropod-borne pathogen transmission-blocking interventions.Parasites & vectors · 2022Review
- The filarial and the antibiotics: Single or combination therapy using antibiotics for filariasis.Frontiers in cellular and infection microbiology · 2022Review
- Disruption of VirB6 Paralogs in Anaplasma phagocytophilum Attenuates Its Growth.Journal of bacteriology · 2020Article
- Advances in Antiwolbachial Drug Discovery for Treatment of Parasitic Filarial Worm Infections.Tropical medicine and infectious disease · 2019Review
- Development of a High-Throughput Cytometric Screen to Identify Anti- Wolbachia Compounds: The Power of Public-Private Partnership.SLAS discovery : advancing life sciences R & D · 2019Article
- Anti-The Indian journal of medical research · 2019Review
- Antifilarial activity of caffeic acid phenethyl ester on Brugia pahangi in vitro and in vivo.Pathogens and global health · 2017Article
- Identification and prioritization of novel anti-Science advances · 2017Article
- Homology modeling of NAD+-dependent DNA ligase of the Wolbachia endosymbiont of Brugia malayi and its drug target potential using dispiro-cycloalkanones.Antimicrobial agents and chemotherapy · 2015Article
- Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis.International journal for parasitology. Drugs and drug resistance · 2014Article
- Wolbachia lipoproteins: abundance, localisation and serology of Wolbachia peptidoglycan associated lipoprotein and the Type IV Secretion System component, VirB6 from Brugia malayi and Aedes albopictus.Parasites & vectors · 2014Article
- Human filarial Wolbachia lipopeptide directly activates human neutrophils in vitro.Parasite immunology · 2014Article
- Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis.Parasitology · 2014Review
- Extensively duplicated and transcriptionally active recent lateral gene transfer from a bacterial Wolbachia endosymbiont to its host filarial nematode Brugia malayi.BMC genomics · 2013Article
- Wolbachia: Can we save lives with a great pandemic?Trends in parasitology · 2013Review
- Current drug targets for helminthic diseases.Parasitology research · 2013Review
- Autophagy regulates Wolbachia populations across diverse symbiotic associations.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Identification and profiling of circulating antigens by screening with the sera from schistosomiasis japonica patients.Parasites & vectors · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphatic filariasis and onchocerciasis are debilitating diseases caused by filarial nematodes. Disease pathogenesis is induced by inflammatory responses following the death of the parasite. Wolbachia endosymbionts of filariae are potent inducers of innate and adaptive inflammation and bacterial lipoproteins have been identified as the ligands that bind toll-like receptors (TLR) 2 and TLR6. Lipoproteins are important structural and functional components of bacteria and therefore enzymes involved in Wolbachia lipoprotein biosynthesis are potential chemotherapeutic targets.
resultsGlobomycin, a signal peptidase II (LspA) inhibitor, has activity against Gram-negative bacteria and a putative lspA gene has been identified from the Wolbachia genome of Brugia malayi (wBm). The amino acids required for function are strictly conserved and functionality was verified by complementation tests in a temperature-sensitive Escherichia coli lspA mutant. Also, transformation of wild type E. coli with Wolbachia lspA conferred significant globomycin resistance. A cell-based screen has been developed utilizing a Wolbachia-containing Aedes albopictus cell line to assay novel compounds active against Wolbachia. Globomycin was screened using this assay, which resulted in a dose-dependent reduction in Wolbachia load. Furthermore, globomycin was also effective in reducing the motility and viability of adult B. malayi in vitro.
conclusionsThese studies validate lipoprotein biosynthesis as a target in an organism for which no genetic tools are available. Further studies to evaluate drugs targeting this pathway are underway as part of the A-WOL drug discovery and development program.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.